title: mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics.
authors.forename: H
authors.initials: H
authors.lastname: Pópulo
authors.forename: P
authors.initials: P
authors.lastname: Soares
authors.forename: A
authors.initials: A
authors.lastname: Faustino
authors.forename: A S
authors.initials: AS
authors.lastname: Rocha
authors.forename: P
authors.initials: P
authors.lastname: Silva
authors.forename: F
authors.initials: F
authors.lastname: Azevedo
authors.forename: J M
authors.initials: JM
authors.lastname: Lopes
mesh_terms: D018450:Disease Progression; D006801:Humans; D008545:Melanoma / Q000175:diagnosis* / Q000201:enzymology* / Q000473:pathology; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000378:metabolism; D011379:Prognosis; D015398:Signal Transduction; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000201:enzymology* / Q000473:pathology; D058570:TOR Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D009363:Neoplasm Proteins; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases